Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsThe tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.
Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.
1.
EVP Beats Cisplatin for Resectable MIBC
2.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
3.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
4.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
5.
A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.
1.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
2.
Prognostic Role of PLAU in Pan-Cancer and Neutrophil Infiltration in Bladder Cancer
3.
CAR T-Cell Therapy: Revolutionizing Hematologic Malignancies
4.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
5.
Managing High Potassium Levels: A Comprehensive Guide to Veltassa
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge